RxDoctor Payments Data

Wendy Fitzgerald

Nurse Practitioner · Martinsburg, WVNPI 1508415910

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.6% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 32.0% of the total. Among nurse practitioner clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,381in general payments, 2019–2025

Across 176 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$688
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$351
  • Otsuka America Pharmaceutical, Inc.$210
  • Neurocrine Biosciences, Inc.$208
  • Teva Pharmaceuticals USA, Inc.$192
  • plus $651 from 9 others

What the payments were for

  • Food & beverage$3,26597%
  • Education$1163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,381 in reported general payments places this provider in the 90th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$6,969
Medicare patients
33
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate19$66,246
AristadaAripiprazole Lauroxil12$40,077
SuboxoneBuprenorphine Hcl/Naloxone Hcl124$29,663
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl174$17,141
Bupropion XlBupropion Hcl94$4,055
Lurasidone Hcl23$3,969
Buspirone Hcl99$1,462
Duloxetine Hcl114$1,382
Ziprasidone Hcl30$1,370
Trazodone Hcl122$1,323
Hydroxyzine Hcl53$1,093
Oxcarbazepine17$1,057
Venlafaxine Hcl ErVenlafaxine Hcl57$1,038
Divalproex Sodium ErDivalproex Sodium31$953
Quetiapine Fumarate36$764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$112$66,24619 claims
Alkermes, Inc.Aristada$688$40,07712 claims
Indivior Inc.Suboxone$48$29,663124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Martinsburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →